ONCAlert | Upfront Therapy for mRCC

Overall Survival Data of the MONARCH-2 Trial in HR+/HER2- Breast Cancer

George Sledge, Jr., MD
Published Online: 8:27 PM, Tue October 1, 2019


George Sledge, Jr., MD, professor of medicine (oncology) at Stanford University Medical Center, discusses the overall survival (OS) data of the phase III MONARCH-2 trial in advanced hormone receptor (HR)–positive, HER2-negative breast cancer.

Data presented at the 2019 ESMO Congress demonstrated that the combination of abemaciclib (Verzenio) and fulvestrant (Faslodex) demonstrated a median 9.4-month OS benefit versus fulvestrant and placebo in patients with advanced HR–positive, HER2-negative breast cancer who progressed on prior endocrine therapy. These data are both statistically significant and clinically important, says Sledge.

At a median follow-up of 47.7 months, the median OS with the combination of abemaciclib and fulvestrant was 46.7 months versus 37.3 months with placebo/fulvestrant (HR, 0.757; 95% CI, 0.606-0.945; P = .0137). MONARCH-2 is part of a suite of trials that have shown significant improvements in progression-free survival and now benefits in OS, further solidifying that these are standard of care treatments, says Sledge. 

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.